First Generic Exclusivity May Not Be Necessary For Competition - FTC Staffer
This article was originally published in The Tan Sheet
Executive Summary
Elimination of the 180-day "first generic" exclusivity provision in the Waxman/Hatch Act may not be harmful to competition, Federal Trade Commission Bureau of Competition Assistant Director for Policy & Evaluation David Balto told the Food & Drug Law Institute annual meeting in Washington, D.C. Dec. 17.
You may also be interested in...
Mylan Wins Argument In Exclusivity Case, But Not Terazosin Approval
Mylan will have to wait until after Feb. 9 to launch its generic terazosin capsules even though the company has won a federal court ruling that Geneva's 180-day exclusivity for the product should have already expired.
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC